Kolon TissueGene, Inc. Q3 revenue KRW 1.6 billion, operating loss KRW 11.7 billion, net profit KRW 120.7 billion
KAI summary · Not investment advice
Kolon TissueGene sold KRW 1.6 billion in Q3 and lost KRW 11.7 billion in its main business, but its net profit turned positive at KRW 120.7 billion.
Operating profit · 3 months
KRW -11.7 billion
Key facts
- Revenue (3 months)
- KRW 1.6 billion
- Net income (3 months)
- KRW 120.7 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 1.7 billion
- Revenue (year to date)
- KRW 3.9 billion
- Operating profit (prior-year 3 months)
- KRW -3.5 billion
- Operating profit (year to date)
- KRW -24.4 billion
- Net income (prior-year 3 months)
- KRW -6.1 billion
- Net income (year to date)
- KRW 73.3 billion
Commentary
AI commentary · Not investment advice
What happened
Kolon TissueGene reported its separate-basis results for the third quarter of 2026. Sales for the 3 months were KRW 1.64 billion. That is 2.5% lower than the same 3 months a year earlier, which were KRW 1.68 billion.
In the company's terms
Operating profit (profit from the core business) for the 3 months was a loss of KRW 11.67 billion. A year earlier, the 3-month operating result was a loss of KRW 3.51 billion.
What changes for shareholders
Net income (the final profit after taxes and all other items) for the 3 months was KRW 120.67 billion. A year earlier it was a loss of KRW 6.09 billion, so the company turned profitable. For the year to date, sales were KRW 3.90 billion. Operating loss was KRW 24.39 billion, and net income was KRW 73.27 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist